(Q43989059)

28 November 2017

title

Repeated courses of alpha-interferon for treatment of chronic hepatitis type B. (English)

1 reference

28 November 2017

1 reference

Janssen HL

1

1 reference

28 November 2017

Schalm SW

2

1 reference

28 November 2017

Berk L

3

1 reference

28 November 2017

de Man RA

4

1 reference

28 November 2017

Heijtink RA

5

1 reference

28 November 2017

publication date

1 January 1993

1 reference

28 November 2017

published in

Journal of Hepatology

1 reference

28 November 2017

volume

17 Suppl 3

1 reference

28 November 2017

page(s)

S47-51

1 reference

Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980423-4

7 January 2021

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980423-4

7 January 2021

Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980423-4

7 January 2021

Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980423-4

7 January 2021

Spontaneous production of tumour necrosis factor alpha and interleukin-1 beta during interferon-alpha treatment of chronic HBV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980423-4

7 January 2021

Immunological studies before and during interferon therapy in chronic HBV infection: identification of factors predicting response

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980423-4

7 January 2021

Changes in interferon receptors on peripheral blood mononuclear cells from patients with chronic hepatitis B being treated with interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980423-4

7 January 2021

Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980423-4

7 January 2021

Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980423-4

7 January 2021

Antiviral effect of prolonged intermittent lymphoblastoid alpha interferon treatment in chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980423-4

7 January 2021

Failure of acyclovir to enhance the antiviral effect of alpha lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis B. A multi-centre randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980423-4

7 January 2021

Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B. A randomized, double-blinded, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980423-4

7 January 2021

Therapy of chronic hepatitis B with recombinant human alpha and gamma interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980423-4

7 January 2021

Treatment of hepatitis B virus infection with interferon. Factors predicting response to interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980423-4

7 January 2021

10.1016/S0168-8278(05)80423-4

Identifiers

DOI

1 reference

28 November 2017

1 reference